AU2002218006A1 - Compositions and methods for the diagnosis of cancer - Google Patents
Compositions and methods for the diagnosis of cancerInfo
- Publication number
- AU2002218006A1 AU2002218006A1 AU2002218006A AU1800602A AU2002218006A1 AU 2002218006 A1 AU2002218006 A1 AU 2002218006A1 AU 2002218006 A AU2002218006 A AU 2002218006A AU 1800602 A AU1800602 A AU 1800602A AU 2002218006 A1 AU2002218006 A1 AU 2002218006A1
- Authority
- AU
- Australia
- Prior art keywords
- fancd2
- sequence
- gene
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G01N33/5758—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008201172A AU2008201172B2 (en) | 2000-11-03 | 2008-03-12 | Methods and Compositions for the Diagnosis of Cancer Susceptibilites and Defective DNA Repair Mechanisms and Treatment Thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24575600P | 2000-11-03 | 2000-11-03 | |
| US60/245,756 | 2000-11-03 | ||
| PCT/US2001/045561 WO2002036761A2 (fr) | 2000-11-03 | 2001-11-02 | Procedes et compositions pour le diagnostic des sensibilites aux cancers et mecanismes de reparation d'adn defectueux et traitement correspondant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002218006A1 true AU2002218006A1 (en) | 2002-05-15 |
Family
ID=22927953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002218006A Abandoned AU2002218006A1 (en) | 2000-11-03 | 2001-11-02 | Compositions and methods for the diagnosis of cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030093819A1 (fr) |
| EP (2) | EP1349924A2 (fr) |
| JP (2) | JP2004536555A (fr) |
| AU (1) | AU2002218006A1 (fr) |
| CA (1) | CA2427802A1 (fr) |
| WO (1) | WO2002036761A2 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030188326A1 (en) | 2000-11-03 | 2003-10-02 | Dana Farber Cancer Institute | Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof |
| US7858331B2 (en) * | 2000-11-03 | 2010-12-28 | Dana Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| CA2465949A1 (fr) | 2001-11-02 | 2003-05-15 | Dana-Farber Cancer Institute | Procedes et compositions de diagnostic des sensibilites au cancer, mecanismes de reparation d'adn defectueux et traitement correspondant |
| US7927840B2 (en) | 2006-09-11 | 2011-04-19 | Gen Probe Incorporated | Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region |
| AU2003298605B2 (en) * | 2002-10-16 | 2007-10-18 | Gen-Probe Incorporated | Compositions and methods for detecting west nile virus |
| US20050009110A1 (en) * | 2003-07-08 | 2005-01-13 | Xiao-Jia Chang | Methods of producing antibodies for diagnostics and therapeutics |
| US8227434B1 (en) | 2003-11-04 | 2012-07-24 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for treating oncological disorders |
| JP2007521811A (ja) | 2004-01-30 | 2007-08-09 | ダナ ファーバー キャンサー インスティテュート | 放射線又は遺伝毒性物質曝露の測定及び定量方法 |
| EP1904088A4 (fr) * | 2005-05-24 | 2010-03-31 | Dana Farber Cancer Inst Inc | Compositions et methodes de traitement du cancer |
| CA2670913A1 (fr) | 2005-12-06 | 2007-06-14 | Oregon Health & Science University | Essai de criblage acellulaire et procedes d'utilisation |
| US20090305266A1 (en) * | 2006-05-03 | 2009-12-10 | Bagby Grover C | Test for ovarian cancer by detecting abnormality in fancd2 pathway |
| US8583380B2 (en) | 2008-09-05 | 2013-11-12 | Aueon, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| WO2011160206A1 (fr) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarqueurs pour lymphomes non hodgkiniens et leurs utilisations |
| US20130195843A1 (en) * | 2010-06-23 | 2013-08-01 | British Columbia Cancer Agency Branch | Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof |
| US9309556B2 (en) | 2010-09-24 | 2016-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target DNA using immobilized primers |
| MA45408A (fr) | 2016-06-17 | 2019-04-24 | Magenta Therapeutics Inc | Compositions et procédés pour la déplétion des cellules cd117+ |
| KR20240161216A (ko) | 2017-01-20 | 2024-11-12 | 하이델베르크 파마 리서치 게엠베하 | Cd137+ 세포의 고갈을 위한 조성물 및 방법 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048729A (en) | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
| IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US6280935B1 (en) | 1994-10-13 | 2001-08-28 | Lynx Therapeutics, Inc. | Method of detecting the presence or absence of a plurality of target sequences using oligonucleotide tags |
| DE69636068T2 (de) | 1995-02-21 | 2006-11-30 | Cantab Pharmaceuticals Research Ltd. | Virale zubereitungen, vektoren, immunogene und impfstoffe |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| NZ326525A (en) | 1995-12-18 | 1999-11-29 | Endorecherche Inc | Chromosome 13-linked breast cancer susceptibility gene |
| US6297010B1 (en) | 1998-01-30 | 2001-10-02 | Genzyme Corporation | Method for detecting and identifying mutations |
| US6287772B1 (en) | 1998-04-29 | 2001-09-11 | Boston Probes, Inc. | Methods, kits and compositions for detecting and quantitating target sequences |
-
2001
- 2001-11-02 WO PCT/US2001/045561 patent/WO2002036761A2/fr not_active Ceased
- 2001-11-02 EP EP01992774A patent/EP1349924A2/fr not_active Withdrawn
- 2001-11-02 EP EP10185041A patent/EP2298878A3/fr not_active Withdrawn
- 2001-11-02 AU AU2002218006A patent/AU2002218006A1/en not_active Abandoned
- 2001-11-02 JP JP2002539507A patent/JP2004536555A/ja active Pending
- 2001-11-02 US US09/998,027 patent/US20030093819A1/en not_active Abandoned
- 2001-11-02 CA CA002427802A patent/CA2427802A1/fr not_active Abandoned
-
2010
- 2010-05-25 JP JP2010119683A patent/JP2010246550A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2298878A3 (fr) | 2011-11-16 |
| EP1349924A2 (fr) | 2003-10-08 |
| US20030093819A1 (en) | 2003-05-15 |
| WO2002036761A3 (fr) | 2003-07-03 |
| EP2298878A2 (fr) | 2011-03-23 |
| JP2010246550A (ja) | 2010-11-04 |
| CA2427802A1 (fr) | 2002-05-10 |
| WO2002036761A9 (fr) | 2002-08-01 |
| JP2004536555A (ja) | 2004-12-09 |
| WO2002036761A2 (fr) | 2002-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2161309C2 (ru) | Мутации гена мтs в зародышевой линии и способ выявления предрасположенности к злокачественным опухолям в гене мтs | |
| KR100599454B1 (ko) | 종양 억제자로 작용하는 aim3의 신규 용도 | |
| JP2010246550A (ja) | 癌感受性の診断のための方法及び組成物並びに欠損dna修復メカニズム及びその処置 | |
| US9354224B2 (en) | Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof | |
| AU707636C (en) | Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof | |
| CA2539837C (fr) | Identification d'antigenes de surface cellulaire associes a une tumeur dans le cadre d'un diagnostic et d'une therapie | |
| ES2537319T3 (es) | Identificación de antígenos asociados a superficies para el diagnóstico y la terapia de tumores | |
| EP0826031B1 (fr) | Gene de l'ataxia-telangiectasie et son organisation genomique | |
| EP0440744A1 (fr) | Produits et procedes de regulation de la suppression du phenotype neoplastique | |
| JPH08510651A (ja) | Mts遺伝子、それにおける変異、およびmts遺伝子配列を用いる癌の診断方法 | |
| RU2164419C2 (ru) | Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts | |
| US7052889B2 (en) | Mammalian SUV39H2 proteins and isolated DNA molecules encoding them | |
| JP2005520543A (ja) | 癌における新規組成物および方法 | |
| EP1451343B1 (fr) | Procedes et compositions de diagnostic des sensibilites au cancer, mecanismes de reparation d'adn defectueux et traitement correspondant | |
| AU2008201172B2 (en) | Methods and Compositions for the Diagnosis of Cancer Susceptibilites and Defective DNA Repair Mechanisms and Treatment Thereof | |
| JP2009039100A (ja) | 癌感受性および欠陥のあるdna修復機構の診断方法および組成物、ならびにそれらを治療するための方法および組成物 | |
| WO2001055450A2 (fr) | GENES AMPLIFIES EN 17q23 | |
| WO2002020848A2 (fr) | Gene et variation de sequence associes au cancer | |
| US20060041111A1 (en) | Dock 3 tumor suppressor gene | |
| US20050089858A1 (en) | Salvador tumor suppressor gene | |
| WO2003062398A2 (fr) | Nouveau gene suppresseur de tumeur, la p28ing5 | |
| Liang | United States Patent te | |
| Iles | The Cell | |
| Eva et al. | 2. Role of the retinoblastoma gene in the oncogenesis | |
| EP2618147A1 (fr) | Réactif pour tester des tumeurs et composition pharmaceutique pour la prévention tumorale |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |